Tags

Type your tag names separated by a space and hit enter

Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia.
Heart Dis. 2003 Jan-Feb; 5(1):72-8.HD

Abstract

Because of their excellent tolerability and their positive impact on lipid parameters, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have become the drugs of first choice for many patients with dyslipidemia. Rosuvastatin is an investigational statin in the U.S. with a number of favorable characteristics, which include low lipophilicity, high hepatocyte selectivity, minimal metabolism, and a low propensity for cytochrome P450 drug interactions. Rosuvastatin has been studied at doses ranging from 1 to 80 mg. In comparative clinical trials, rosuvastatin given at 5 to 10 mg/day reduced low-density lipoprotein cholesterol to a significantly greater extent than atorvastatin 10 mg/day, pravastatin 20 mg/day, and simvastatin 20 mg/day. In addition, rosuvastatin exhibited beneficial effects on other lipid parameters such as high-density lipoprotein cholesterol and triglycerides. Rosuvastatin's safety profile was demonstrated to be similar to those of other statins. Given its favorable pharmacokinetic and pharmacodynamic characteristics, rosuvastatin is likely to become a valuable addition to the statin drug class. The author reviews the pharmacologic and pharmacokinetic properties of this new statin.

Authors+Show Affiliations

Department of Pharmacy, Montefiore Medical Center, Bronx, New York 10461, USA. Acheng@Montefiore.org

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

12549990

Citation

Cheng-Lai, Angela. "Rosuvastatin: a New HMG-CoA Reductase Inhibitor for the Treatment of Hypercholesterolemia." Heart Disease (Hagerstown, Md.), vol. 5, no. 1, 2003, pp. 72-8.
Cheng-Lai A. Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia. Heart Dis. 2003;5(1):72-8.
Cheng-Lai, A. (2003). Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia. Heart Disease (Hagerstown, Md.), 5(1), 72-8.
Cheng-Lai A. Rosuvastatin: a New HMG-CoA Reductase Inhibitor for the Treatment of Hypercholesterolemia. Heart Dis. 2003 Jan-Feb;5(1):72-8. PubMed PMID: 12549990.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia. A1 - Cheng-Lai,Angela, PY - 2003/1/29/pubmed PY - 2003/5/17/medline PY - 2003/1/29/entrez SP - 72 EP - 8 JF - Heart disease (Hagerstown, Md.) JO - Heart Dis VL - 5 IS - 1 N2 - Because of their excellent tolerability and their positive impact on lipid parameters, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have become the drugs of first choice for many patients with dyslipidemia. Rosuvastatin is an investigational statin in the U.S. with a number of favorable characteristics, which include low lipophilicity, high hepatocyte selectivity, minimal metabolism, and a low propensity for cytochrome P450 drug interactions. Rosuvastatin has been studied at doses ranging from 1 to 80 mg. In comparative clinical trials, rosuvastatin given at 5 to 10 mg/day reduced low-density lipoprotein cholesterol to a significantly greater extent than atorvastatin 10 mg/day, pravastatin 20 mg/day, and simvastatin 20 mg/day. In addition, rosuvastatin exhibited beneficial effects on other lipid parameters such as high-density lipoprotein cholesterol and triglycerides. Rosuvastatin's safety profile was demonstrated to be similar to those of other statins. Given its favorable pharmacokinetic and pharmacodynamic characteristics, rosuvastatin is likely to become a valuable addition to the statin drug class. The author reviews the pharmacologic and pharmacokinetic properties of this new statin. SN - 1521-737X UR - https://www.unboundmedicine.com/medline/citation/12549990/Rosuvastatin:_a_new_HMG_CoA_reductase_inhibitor_for_the_treatment_of_hypercholesterolemia_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=linkout&SEARCH=12549990.ui DB - PRIME DP - Unbound Medicine ER -